Orthopedics and PRP and Stem Cells! Have you seen our Instagram site recently?…We are adding ever 250 followers a week and just added our 2000th follower. On IG I mix in fun tips and tidbits, clinical tips, short interviews on hot topics (like commenting on the umbilical cord blood hashtag#scam “Stem Cell” injection the actor who played Superman recently got from a nurse in Beverly Hills.
We have done hundreds and hundreds of bone marrow aspirations and PRP injections in the office! Don’t let anyone tell you that you have to go to the hospital or a surgery center to get these procedures done. Average procedure time for PRP: 30 minutes Average procedure time for bone marrow concentrate: 45 min.
#1. There are no living stem cells in frozen, shipped umbilical cord or amniotic fluid or Wharton’s Jelly or placenta
#2. The FDA has ruled that these products are unapproved biologic drugs when used for orthopedic conditions (ie. illegal to give)
Interesting Canadian pilot study (N=12) on cultured bone marrow derived MSCs used for knee osteoarthritis (KL3 and KL4) This is one of the very few published papers showing dose dependent outcomes (higher dose…better outcome) with autologous cultured bone marrow derived MSCs.
The Park Avenue Stem Cell clinic is a former Cell Surgical Network affiliate which is a network whose founders (Drs. Mark Berman and Dr. Elliot Lander, are currently entangled with their own legal struggles with the USA Justice department over their stem cell clinic claims and activities.
Come get honest answers to all of your questions about PRP and stem cells in orthopedics. Learn how to avoid stem cell scams ….anything not from your own body or from out of a bottle is NOT a stem cell injection…run away, run away!
FDA Just Reaffirmed That You Can’t Use Umbilical Cord Blood in Orthopedics Without A Drug License Or Specific Permission Thru a RMAT Or Other FDA Program
FDA clearly states that umbilical cord blood is NOT exempt from registering as a biologics drug under section 351.
FDA states that “….using the umbilical cord blood products to treat orthopedic conditions is not homologous use as defined in 21 CFR 1271.3(c).”